AVUV vs IBB
Avantis US Small Cap Value ETF vs iShares Biotechnology ETF
- • AVUV has the lower expense ratio at 0.25% vs 0.44% for IBB.
- • AVUV pays a higher dividend yield (1.23%).
Side-by-side metrics
| Metric | AVUV | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.25% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.23% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $32.47B | $11.50B |
YTD return | 21.28% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 0.60 |
P/E ratio | 11.39 | 25.48 |
Last price | $122.88 | $217.75 |
Inception | — | — |
Issuer | Avantis | iShares |
AVUV top holdings
| GATX | GATX Corp | 0.96% |
| MATX | Matson Inc | 0.95% |
| SM | SM Energy Co | 0.85% |
| ANF | Abercrombie & Fitch Co Class A | 0.78% |
| VSAT | Viasat Inc | 0.78% |
| CROX | Crocs Inc | 0.77% |
| M | Macy's Inc | 0.77% |
| LYFT | Lyft Inc Class A | 0.76% |
| MUR | Murphy Oil Corp | 0.74% |
| LEA | Lear Corp | 0.71% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About AVUV
AVUV (Avantis US Small Cap Value ETF) is US small-cap value with profitability screen. Managed by Avantis, the fund carries $32.5B in assets under management, an expense ratio of 0.25%, a dividend yield of 1.23%. Its largest holding is GATX Corp (GATX), which represents 1.0% of the portfolio. Real Estate is the fund's largest sector exposure at 0.6%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.